FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Northwest Biotherapeutics restarts DCVax trial enrollment

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


After a two-year postponement, Northwest Biotherapeutics has started enrolling patients in a 240-patient clinical study of DCVax, its brain cancer vaccine. Previously, the trial had 33 patients and was conducted at 13 sites. But the trial was never suspended, and the enrolled subjects have continued to receive treatment even though no new patients have been admitted into the study.

"We never suspended the trial," explained Northwest Biotherapeutics' Chairman of the Board, Linda Powers, to MarketWatch. "We found and spent the money to keep the trial open and we kept treating those who had already enrolled. During the worst of this Great Recession, we did preserve our resources by not enrolling any new patients on top of the couple dozen patients already enrolled and being treated at our 13 trial sites across the country, in anticipation of continuing our positive clinical results and a broader economic revival."

For now, Powers won't comment on partnerships or other funding opportunities; she is focusing on the trial and moving DCVax forward. Northwest Biotherapeutics has also received FDA approval to start more Phase I trials for five other cancers.

"We are ecstatic that Northwest Biotherapeutics has resumed patient enrollment in the ongoing Phase II clinical trial, which has several dozen patients already enrolled. The preliminary results of the clinical data are showing more promise than any other treatments that the brain tumor community has seen in over 20 years," stated Barb Gibbs, executive director of Miles for Hope, in a release.

- see the Miles for Hope release
- read MarketWatch's coverage

Related Articles:
Researchers explore brain cancer vaccine
Charity bankrolls brain cancer vaccine trial

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about brain cancer   Northwest Biotherapeutics  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.